• Explore /
  • Poster
  • / A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).

A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).

Abstract Poster

Authors

Ahmad Tarhini

Ahmad A. Tarhini

University of Pittsburgh Cancer Institute, Pittsburgh, PA

Ahmad A. Tarhini , Sandra J. Lee , Uma N. M. Rao , Arun Nagarajan , Mark R. Albertini , Jerry W Mitchell Jr., Stuart J. Wong , Mark A. Taylor , Noel Laudi , Phu Van Truong , Robert Martin Conry , John M. Kirkwood

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01708941

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9542)

DOI

10.1200/JCO.2017.35.15_suppl.9542

Abstract #

9542

Poster Bd #

150

Abstract Disclosures

Similar Posters

First Author: Geoffrey Thomas Gibney

First Author: Suzanne Phillips

First Author: Viktor Grünwald

First Author: Ari M. Vanderwalde